Literature DB >> 33208882

TFEB rearranged renal cell carcinoma. A clinicopathologic and molecular study of 13 cases. Tumors harboring MALAT1-TFEB, ACTB-TFEB, and the novel NEAT1-TFEB translocations constantly express PDL1.

Anna Caliò1, Shuko Harada2, Matteo Brunelli1, Serena Pedron1, Diego Segala3, Sofia Canete Portillo2, Cristina Magi-Galluzzi2, George J Netto2, Alexander C Mackinnon2, Guido Martignoni4,5.   

Abstract

Renal cell carcinomas with t(6;11) chromosome translocation has been classically characterized by the rearrangement of the TFEB gene, located on chromosome 6, and MALAT1 gene, located on chromosome 11. Recently, a few other genes have been described as fusion partners in TFEB rearranged renal cell carcinomas. Although most of TFEB rearranged renal cell carcinomas have an indolent behavior, in the rare cases of advanced metastatic disease targeted therapy and predictive markers remain lacking. In the present study, we collected 13 TFEB rearranged renal cell carcinomas, confirmed by FISH, analyzing their morphology and exploring the novel gene partners. Looking for predictive markers, we have also performed PDL1 immunohistochemical analysis by using four different assays (E1L3N, 22C3, SP142, and SP263). MALAT1 gene rearrangement has been found in ten tumors, five cases showing classical biphasic morphology with "rosettes", five cases without "rosettes" mimicking other renal cell carcinomas or epithelioid angiomyolipoma/pure epithelioid PEComa. We identified two different partner genes, ACTB and NEAT1, the latter previously unreported and occurring in a tumor with an unusual solid and cystic appearance. In both cases, the "rosettes" were absent. In one case no gene partner was identified. Overall, in 12 of 13 TFEB-rearranged renal cell carcinomas staining for PDL1 SP263 was observed, whereas the other antibodies were less reliable or more difficult to interpret. In conclusion, we described the third case of ACTB-TFEB rearranged renal cell carcinoma and a novel NEAT1-TFEB rearranged renal cell carcinoma, both without the distinctive biphasic morphology typical of t(6;11) renal cell carcinoma. Finally, PDL1 SP263 was constantly expressed in TFEB rearranged renal cell carcinoma with possible clinical benefit which requires further investigations.

Entities:  

Year:  2020        PMID: 33208882     DOI: 10.1038/s41379-020-00713-6

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  7 in total

1.  TFE3 and TFEB-rearranged renal cell carcinomas: an immunohistochemical panel to differentiate from common renal cell neoplasms.

Authors:  Anna Caliò; Stefano Marletta; Matteo Brunelli; Serena Pedron; Sofia Canete Portillo; Diego Segala; Elena Bariani; Stefano Gobbo; George Netto; Guido Martignoni
Journal:  Virchows Arch       Date:  2022-08-18       Impact factor: 4.535

2.  A primary rectal neoplasm with novel DDX5-TFEB fusion.

Authors:  Mengxin Zhang; Xiaoxue Yin; Junru Chen; Sha Zhu; Linmao Zheng; Hao Zeng; Qiao Zhou; Ni Chen
Journal:  Virchows Arch       Date:  2022-04-09       Impact factor: 4.535

Review 3.  A review of neoplasms with MITF/MiT family translocations.

Authors:  Shuanzeng Wei; Joseph R Testa; Pedram Argani
Journal:  Histol Histopathol       Date:  2022-02-02       Impact factor: 2.303

4.  Role of SIRT1/AMPK signaling in the proliferation, migration and invasion of renal cell carcinoma cells.

Authors:  Xin Wang; Youlu Lu; Zhouting Tuo; Huan Zhou; Ying Zhang; Zhangjun Cao; Longfei Peng; Dexin Yu; Liangkuan Bi
Journal:  Oncol Rep       Date:  2021-04-28       Impact factor: 3.906

Review 5.  MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights.

Authors:  Audrey Simonaggio; Damien Ambrosetti; Virginie Verkarre; Marie Auvray; Stéphane Oudard; Yann-Alexandre Vano
Journal:  Int J Mol Sci       Date:  2022-07-11       Impact factor: 6.208

Review 6.  Cathepsin K: A Novel Diagnostic and Predictive Biomarker for Renal Tumors.

Authors:  Anna Caliò; Matteo Brunelli; Stefano Gobbo; Pedram Argani; Enrico Munari; George Netto; Guido Martignoni
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

7.  LncRNA NEAT1 Enhances Glioma Progression via Regulating the miR-128-3p/ITGA5 Axis.

Authors:  Jiakai Chen; Handong Wang; Junjun Wang; Wenhao Niu; Chulei Deng; Mengliang Zhou
Journal:  Mol Neurobiol       Date:  2021-07-15       Impact factor: 5.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.